NEW YORK (GenomeWeb News) – Nuclea Biotechnologies this week announced Immuno-Biological Laboratories will be the primary US distributor of Nuclea's HER-2/neu kits.

Nuclea and IBL also will coordinate joint marketing efforts for the serum HER-2/neu kits as part of the deal.

The microtiter-based test measures the level of HER-2/neu in serum and is used to monitor metastatic breast cancer. Based in Minneapolis, IBL distributes diagnostic assays for autoimmunity, endocrinology, infectious disease, oncology, and neuroscience. It also offers laboratory services.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.